
Experience
Araris Biotech’s up to $1.14 Billion Acquisition by Taiho Pharmaceutical
March 17, 2025
Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.
Related contacts
Related Practices & Industries
PetLab Co. Announces Majority Stake Sale to BC Partners
February 26, 2025
Cooley advised PetLab Co., a rapidly growing independent pet supplement brand headquartered in London, on its majority stake sale to BC Partners, a top international investment firm.
Related contacts
Related Practices & Industries
Kura Oncology Announces Global Strategic Collaboration With Kyowa Kirin
November 20, 2024
Cooley advised clinical-stage biopharmaceutical company Kura Oncology (Nasdaq: KURA) on its global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib, Kura’s selective oral menin inhibitor that is being investigated for the treatment of acute myeloid leukemia and other hematologic malignancies.
Related contacts
Related Practices & Industries
AGS Announces Definitive Agreement to Be Acquired by Brightstar Capital Partners for $1.1 Billion
May 9, 2024
Cooley advised PlayAGS, a global gaming supplier of high-performing slots, tables and interactive products, on its definitive agreement to be acquired by the affiliates of Brightstar Capital Partners for $1.1 billion.
Related contacts
Related Practices & Industries
CallTower Receives Investment From BV Investment Partners
November 16, 2023
Cooley advised CallTower, an international leader in delivering cloud-based, enterprise-class communications, contact center and collaboration solutions, on its investment from BV Investment Partners.
Related contacts
Related Practices & Industries
Admissions and credentials
Brussels, Belgium
Spain